Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2011
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Osaka Securities Exchange containing financial results for the quarter ended September 30, 2011. This filing serves as Regulation FD disclosure, noting that the Tanshin is substantially the same as the Company's Form 10-Q for the same period, with supplemental full-year guidance.
Key Financial Metrics
The filing provides full-year 2011 estimates rather than specific quarterly results for the period ended September 30, 2011.
| Metric | Full Year 2011 Estimate |
|---|---|
| Revenues | $0 (None expected) |
| Operating Loss | $(15,721,000) |
| Net Loss | $(18,678,000) |
| Loss Per Share (Basic & Diluted) | $(1.28) |
| Weighted Average Shares | 14,643,992 |
Note: The filing does not provide specific values for cash flow, debt, or liquidity in this text. Financial statements denominated in Japanese yen were disclosed in the Tanshin using an exchange rate of 77.75 JPY/USD as of October 31, 2011.
Material Changes and Guidance
Guidance Update: The Company has not changed its estimated results for the full year ending December 31, 2011, from those previously provided in the Kessan Tanshin filed on May 17, 2011.
Material Changes: The filing does not explicitly detail material changes in financial position versus the prior comparable period, as it focuses on reaffirming the full-year forecast.
Management Commentary, Risks, and Contingencies
- Forward-Looking Statements: Management emphasizes that estimates are based on assumptions regarding current conditions and trends. Actual results may differ materially due to risks beyond the Company's control.
- Clinical and Development Risks: Key risks include uncertainty in clinical trial results, regulatory approval delays, and reliance on third parties for manufacturing and trials.
- Strategic Risks: Risks involve the integration of the Avigen, Inc. acquisition, the combination of ibudilast development programs, and the ability to secure strategic collaborations.
- Financial Risks: The Company faces risks regarding the availability of funds to complete product development and the ability to raise sufficient capital. Market factors, including credit market uncertainties and currency exchange rate fluctuations, are also cited.
- Auditor Disclaimer: Independent auditors have not compiled or been involved in the preparation of the forecasted financial results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the specific quarterly revenue and expense figures in the Form 10-Q for the quarter ended September 30, 2011, as this 8-K only provides full-year estimates.
- Confirm the Company's current cash position and liquidity runway, as this filing does not disclose specific cash flow or debt levels.
- Review the status of the Avigen, Inc. acquisition integration and the combined ibudilast development program.
- Assess the progress of ongoing clinical trials and any recent regulatory communications.
- Monitor capital market conditions and the Company's ability to raise additional funding as needed.